Pharmaphorum — An entirely new category of medicine is emerging, and a new wave of digital therapeutics start-ups is joining the effort to bring meaning and definition to this new industry.
Although the digital therapeutics sector is still only in its early phases, the frontrunners have already covered some important ground, laying its first foundations in terms of how the medical software interventions are seen and defined.
In recognition of the promise of digital therapeutics, they have this year been added to Bayer’s G4A programme – which is open for applications until May 31. The digital health accelerator is particularly on the lookout for impactful digital therapeutics solutions that can be applied in oncology, women’s health or the cardio-renal area.
To get an inside view on progress within the digital therapeutics sector, we spoke with the Digital Therapeutics Alliance’s executive director Megan Coder, who also discussed how digital therapeutics start-ups can advance their solutions and collaborate with the industry alliance she heads up.
Better Therapeutics, a developer of prescription digital therapeutics for the treatment of cardiometabolic diseases, today announced an upcoming poster presentation of health economic data at the ISPOR 2019 Conference May 18 – 22 in New Orleans. The presentation will include data on the reduction of health resource utilization and cost-effectiveness of Better’s digital behavioral intervention in type 2 diabetes and hypertension.
Recognizing there are few existing assessments of the economic benefits of digital therapeutics, Better commissioned health economic and outcomes research (HEOR) to understand the cost-effectiveness of its intervention by analysing both economic and clinical benefit. The poster presentation will present selected data from that research.
NEW HAVEN, Connecticut–(FORBES)–Professional groups and industry-wide collaborations are emerging to drive the growth of healthcare innovation. The development of high-quality, evidence-based products and services is now being supported by the Digital Medicine Society (DiMe) as well as the existing Digital Therapeutic Alliance (DTA).
The use of digital tools for better diagnosis and outcomes is rapidly progressing. The global digital health market is expected to reach $223.7 billion within five years based on increasing penetration of mobile devices, remote patient monitoring, and growing demand for advanced information systems. These products could represent a fundamental shift in healthcare services and actionable data generation according to experts.
Globes — French pharmaceutical company Sanofi has announced that it is entering the “beyond drug” sector – support for drug prescriptions with a digital envelope. Its partner will be Happify Health, founded by Israelis in the US.
The first products are designed to treat patients suffering from depression and multiple sclerosis patients. The idea is for these products to be approved for marketing as drugs after undergoing clinical trials in combination with the drug and the ability of the applications to improve the situation of the patients is proven.
May 15, 2019 – The DCRI will bring its regulatory experience and clinical expertise to the conversation surrounding digital therapeutics.
The DCRI has joined a new alliance focused on bringing digital therapeutics solutions to patients.
The Digital Therapeutics Alliance (DTA), formed in 2017, works to improve access to digital therapeutics for patients, providers, and payers, in an effort to reduce costs and enhance individualized health care. The DTA currently has 25 members, and the DCRI is the first academic member.
“The DTA seeks to broaden the global digital therapeutics conversation within their organization, and the DCRI brings a different perspective,” said the DCRI’s Scott Kollins, PhD (pictured top), who helped lead the DCRI’s application process to join the alliance. “This is a good way for to us to continue and amplify our work in digital therapeutics and potentially become leaders in the space.”
SEVEN HILLS, Ohio–(BUSINESS WIRE)–Anthem Blue Cross and Blue Shield in Ohio (Anthem) today announced the rollout of an innovative new program, with Propeller Health’s collaboration, to help improve health outcomes for Ohio consumers enrolled in Anthem’s Medicare Advantage health plans who have chronic obstructive pulmonary disease (COPD).
“This collaboration between Anthem and Propeller gives individuals access to connected care technology that will help them more easily manage their COPD, in order to help them have a better quality of life. Anthem will continue to focus on improving consumers’ healthcare experience by increasing access to high-quality, meaningful solutions.”
SAN FRANCISCO, May 20, 2019 (GLOBE NEWSWIRE) — Big Health, a digital therapeutics company dedicated to helping millions back to good mental health, today announced over 12 million people now have access to their flagship product, Sleepio.
Thanks to a partnership with the UK’s National Health Service (NHS), 8 million Londoners and 2.3 million in the Thames Valley now have free access to Sleepio, an evidence-based digital therapeutic for poor sleep. Combined with another 2 million covered employees at Big Health employer customers in the United States, Big Health’s total covered population amounts to over 12 million individuals.
Big Health, a digital therapeutics company dedicated to helping millions back to good mental health, today announced over 12 million people now have access to their flagship product, Sleepio.
Thanks to a partnership with the UK’s National Health Service (NHS), 8 million Londoners and 2.3 million in the Thames Valley now have free access to Sleepio, an evidence-based digital therapeutic for poor sleep. Combined with another 2 million covered employees at Big Health employer customers in the United States, Big Health’s total covered population amounts to over 12 million individuals.
Milwaukee, WI and Columbia, MD – May 14, 2019 – The Business Health Care Group (BHCG), a coalition of employers located throughout eastern Wisconsin, recently announced a partnership with Welldoc, a leading digital therapeutic company working with individuals with chronic diseases. The company will offer its award-winning digital assistant BlueStar program to BHCG member employers at preferred rates. BlueStar is a web and mobile in-app coach designed to engage people with type 2 diabetes. It delivers precision-based real-time feedback, diabetes educational tools, and provides actionable insights to the user’s care team to optimize care.
The program is available to employers and their plan participants, both locally and nationally (including outside of the BHCG 22-county Wisconsin region), either through full BHCG membership or on a stand-alone basis.
Recorded live from the MM&M Transforming Healthcare conference at the Edison Ballroom in midtown Manhattan, this episode of the podcast features Megan Coder, executive director of the Digital Therapeutics Alliance. She and MM&M’s executive editor Marc Iskowitz talk about the leading firms in digital therapeutics, what the relationship is between DTx firms and pharma/payers and how those in the discipline are using real world evidence studies to prove their value.